Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab

Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable...

Descripción completa

Detalles Bibliográficos
Autores principales: Cludts, Isabelle, Spinelli, Francesca Romana, Morello, Francesca, Hockley, Jason, Valesini, Guido, Wadhwa, Meenu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484178/
https://www.ncbi.nlm.nih.gov/pubmed/28279855
http://dx.doi.org/10.1016/j.cyto.2017.02.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484178/
https://www.ncbi.nlm.nih.gov/pubmed/28279855
http://dx.doi.org/10.1016/j.cyto.2017.02.015

Ejemplares similares